Alemtuzumab is safe and effective as immunosuppressive treatment for aplastic anaemia and single-lineage marrow failure: a pilot study and a survey from the EBMT WPSAA

Antonio Maria Risitano; Carmine Selleri; Bianca Serio; Giovanni Fernando Torelli; Alexander Kulagin; Sebastien Maury; Joerg Halter; Vikas Gupta; Andrea Bacigalupo; Gerard Socie; Andre Tichelli; Hubert Schrezenmeier; Judith Marsh; Jakob Passweg; Bruno Rotoli; European Grp Blood Marrow

doi:10.1111/j.1365-2141.2009.08027.x

Alemtuzumab is safe and effective as immunosuppressive treatment for aplastic anaemia and single-lineage marrow failure: a pilot study and a survey from the EBMT WPSAA

Antonio Maria Risitano^*, Carmine Selleri, Bianca Serio, Giovanni Fernando Torelli, Alexander Kulagin, Sebastien Maury, Joerg Halter, Vikas Gupta, Andrea Bacigalupo, Gerard Socie, Andre Tichelli, Hubert Schrezenmeier, Judith Marsh, Jakob Passweg, Bruno Rotoli, European Grp Blood Marrow

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

63 Citations (Scopus)

Abstract

An alemtuzumab-based experimental immunosuppressive treatment (IST) regimen was investigated in 35 patients with severe aplastic anaemia (SAA), pure red cell (PRCA) or pure white cell aplasia (PWCA). Alemtuzumab total dose was 73-103 mg s.c., followed by cyclosporine. No serious toxicity due to the regimen was observed. Adverse events were clinically irrelevant; infectious events were rare. The total response rate was 58%, 84% and 100% in SAA, PRCA and PWCA, respectively, with corresponding 6 months cumulative response probabilities of 84%, 84% and 100%. Subcutaneous alemtuzumab is a feasible and sufficiently safe IST regimen for patients suffering from immune-mediated marrow failures.

Original language	English
Pages (from-to)	791-796
Number of pages	6
Journal	British Journal of Haematology
Volume	148
Issue number	5
DOIs	https://doi.org/10.1111/j.1365-2141.2009.08027.x
Publication status	Published - Mar 2010

Keywords

alemtuzumab
aplastic anaemia
pure red cell aplasia
pure white cell aplasia
bone marrow failure
RED-CELL APLASIA
ANTITHYMOCYTE GLOBULIN
REMISSION
CYCLOSPORINE
CAMPATH-1H
THERAPY
LEUKEMIA

Access to Document

10.1111/j.1365-2141.2009.08027.x

Cite this

Risitano, A. M., Selleri, C., Serio, B., Torelli, G. F., Kulagin, A., Maury, S., Halter, J., Gupta, V., Bacigalupo, A., Socie, G., Tichelli, A., Schrezenmeier, H., Marsh, J., Passweg, J., Rotoli, B., & European Grp Blood Marrow (2010). Alemtuzumab is safe and effective as immunosuppressive treatment for aplastic anaemia and single-lineage marrow failure: a pilot study and a survey from the EBMT WPSAA. British Journal of Haematology, 148(5), 791-796. https://doi.org/10.1111/j.1365-2141.2009.08027.x

@article{85f548714f9a4021a3629575cda2b423,

title = "Alemtuzumab is safe and effective as immunosuppressive treatment for aplastic anaemia and single-lineage marrow failure: a pilot study and a survey from the EBMT WPSAA",

abstract = "An alemtuzumab-based experimental immunosuppressive treatment (IST) regimen was investigated in 35 patients with severe aplastic anaemia (SAA), pure red cell (PRCA) or pure white cell aplasia (PWCA). Alemtuzumab total dose was 73-103 mg s.c., followed by cyclosporine. No serious toxicity due to the regimen was observed. Adverse events were clinically irrelevant; infectious events were rare. The total response rate was 58%, 84% and 100% in SAA, PRCA and PWCA, respectively, with corresponding 6 months cumulative response probabilities of 84%, 84% and 100%. Subcutaneous alemtuzumab is a feasible and sufficiently safe IST regimen for patients suffering from immune-mediated marrow failures.",

keywords = "alemtuzumab, aplastic anaemia, pure red cell aplasia, pure white cell aplasia, bone marrow failure, RED-CELL APLASIA, ANTITHYMOCYTE GLOBULIN, REMISSION, CYCLOSPORINE, CAMPATH-1H, THERAPY, LEUKEMIA",

author = "Risitano, {Antonio Maria} and Carmine Selleri and Bianca Serio and Torelli, {Giovanni Fernando} and Alexander Kulagin and Sebastien Maury and Joerg Halter and Vikas Gupta and Andrea Bacigalupo and Gerard Socie and Andre Tichelli and Hubert Schrezenmeier and Judith Marsh and Jakob Passweg and Bruno Rotoli and {European Grp Blood Marrow}",

year = "2010",

month = mar,

doi = "10.1111/j.1365-2141.2009.08027.x",

language = "English",

volume = "148",

pages = "791--796",

journal = "British Journal of Haematology",

issn = "0007-1048",

publisher = "Wiley-Blackwell Publishing Ltd",

number = "5",

}

Risitano, AM, Selleri, C, Serio, B, Torelli, GF, Kulagin, A, Maury, S, Halter, J, Gupta, V, Bacigalupo, A, Socie, G, Tichelli, A, Schrezenmeier, H, Marsh, J, Passweg, J, Rotoli, B & European Grp Blood Marrow 2010, 'Alemtuzumab is safe and effective as immunosuppressive treatment for aplastic anaemia and single-lineage marrow failure: a pilot study and a survey from the EBMT WPSAA', British Journal of Haematology, vol. 148, no. 5, pp. 791-796. https://doi.org/10.1111/j.1365-2141.2009.08027.x

Alemtuzumab is safe and effective as immunosuppressive treatment for aplastic anaemia and single-lineage marrow failure: a pilot study and a survey from the EBMT WPSAA. / Risitano, Antonio Maria; Selleri, Carmine; Serio, Bianca et al.
In: British Journal of Haematology, Vol. 148, No. 5, 03.2010, p. 791-796.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Alemtuzumab is safe and effective as immunosuppressive treatment for aplastic anaemia and single-lineage marrow failure

T2 - a pilot study and a survey from the EBMT WPSAA

AU - Risitano, Antonio Maria

AU - Selleri, Carmine

AU - Serio, Bianca

AU - Torelli, Giovanni Fernando

AU - Kulagin, Alexander

AU - Maury, Sebastien

AU - Halter, Joerg

AU - Gupta, Vikas

AU - Bacigalupo, Andrea

AU - Socie, Gerard

AU - Tichelli, Andre

AU - Schrezenmeier, Hubert

AU - Marsh, Judith

AU - Passweg, Jakob

AU - Rotoli, Bruno

AU - European Grp Blood Marrow

PY - 2010/3

Y1 - 2010/3

N2 - An alemtuzumab-based experimental immunosuppressive treatment (IST) regimen was investigated in 35 patients with severe aplastic anaemia (SAA), pure red cell (PRCA) or pure white cell aplasia (PWCA). Alemtuzumab total dose was 73-103 mg s.c., followed by cyclosporine. No serious toxicity due to the regimen was observed. Adverse events were clinically irrelevant; infectious events were rare. The total response rate was 58%, 84% and 100% in SAA, PRCA and PWCA, respectively, with corresponding 6 months cumulative response probabilities of 84%, 84% and 100%. Subcutaneous alemtuzumab is a feasible and sufficiently safe IST regimen for patients suffering from immune-mediated marrow failures.

AB - An alemtuzumab-based experimental immunosuppressive treatment (IST) regimen was investigated in 35 patients with severe aplastic anaemia (SAA), pure red cell (PRCA) or pure white cell aplasia (PWCA). Alemtuzumab total dose was 73-103 mg s.c., followed by cyclosporine. No serious toxicity due to the regimen was observed. Adverse events were clinically irrelevant; infectious events were rare. The total response rate was 58%, 84% and 100% in SAA, PRCA and PWCA, respectively, with corresponding 6 months cumulative response probabilities of 84%, 84% and 100%. Subcutaneous alemtuzumab is a feasible and sufficiently safe IST regimen for patients suffering from immune-mediated marrow failures.

KW - alemtuzumab

KW - aplastic anaemia

KW - pure red cell aplasia

KW - pure white cell aplasia

KW - bone marrow failure

KW - RED-CELL APLASIA

KW - ANTITHYMOCYTE GLOBULIN

KW - REMISSION

KW - CYCLOSPORINE

KW - CAMPATH-1H

KW - THERAPY

KW - LEUKEMIA

U2 - 10.1111/j.1365-2141.2009.08027.x

DO - 10.1111/j.1365-2141.2009.08027.x

M3 - Article

SN - 0007-1048

VL - 148

SP - 791

EP - 796

JO - British Journal of Haematology

JF - British Journal of Haematology

IS - 5

ER -

Alemtuzumab is safe and effective as immunosuppressive treatment for aplastic anaemia and single-lineage marrow failure: a pilot study and a survey from the EBMT WPSAA

Abstract

Keywords

Access to Document

Fingerprint

Cite this